An Integrated Human/Murine Transcriptome and Pathway Approach to Identify Prenatal Treatments for Down Syndrome

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guedj, Faycal ^a   Pennings, Jeroen La ^b   Massingham, Lauren J ^a   Wick, Heather C ^c   Siegel, Ashley E ^a   Tantravahi, Umadevi ^d   Bianchi, Diana W ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Tufts University   (United States)

^d WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TTC3 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; USP16 PROTEIN, HUMAN;

ANIMAL; BRAIN; DISEASE MODEL; DOWN SYNDROME; DRUG EFFECT; FEMALE; FETUS; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; MAMMALIAN EMBRYO; METABOLISM; MOLECULAR LIBRARY; MOUSE; PATHOLOGY; PHARMACOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BRAIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOWN SYNDROME; EMBRYO, MAMMALIAN; FEMALE; FETUS; GENE DOSAGE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE REGULATORY NETWORKS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SYSTEMS BIOLOGY; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84986293293     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32353     Document Type: Article

References (70)

1. Haydar, T. F. & Reeves, R. H. Trisomy 21 and early brain development. Trends Neurosci. 35, 81-91 (2012).
2. Guedj, F., Bianchi, D. W. & Delabar, J. M. Prenatal treatment of Down syndrome: a reality? Curr. Opin. Obstet. Gynecol. 26, 92-103 (2014).
3. Guedj, F. & Bianchi, D. W. Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome. Prenat. Diagn. 33, 614-618 (2013).
4. Slonim, D. K. et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc. Natl. Acad. Sci. USA 106, 9425-9429 (2009).
5. Hui, L. et al. Novel neurodevelopmental information revealed in amniotic fluid supernatant transcripts from fetuses with trisomies 18 and 21. Hum. Genet. 131, 1751-1759 (2012).
6. Hui, L., Wick, H. C., Edlow, A. G., Cowan, J. M. & Bianchi, D. W. Global gene expression analysis of term amniotic fluid cell-free fetal RNA. Obstet. Gynecol. 121, 1248-1254 (2013).
7. Weick, J. P. et al. Deficits in human trisomy 21 iPSCs and neurons. Proc. Natl. Acad. Sci. USA 110, 9962-9967 (2013).
8. Mao, R., Zielke, C. L., Zielke, H. R. & Pevsner, J. Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 81, 457-467 (2003).
9. Mao, R. et al. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol. 6, R107 (2005).
10. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, disease. Science 313, 1929-1935 (2006).
11. Lamb, J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer. 7, 54-60 (2007).
12. Guedj, F. et al. The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome. Am. J. Med. Genet. A. 167A, 1993-2008 (2015).
13. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57, 289-300 (1995).
14. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
15. Wick, H. C. et al. DFLAT: functional annotation for human development. BMC Bioinformatics 15, 45-2105-15-45 (2014).
16. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
17. Briggs, J. A. et al. Integration-free induced pluripotent stem cells model genetic and neural developmental features of Down syndrome etiology. Stem Cells 31, 467-478 (2013).
18. Li, C. M. et al. Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. BMC Med. Genet. 7, 24 (2006).
19. Ait Yahya-Graison, E. et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 81, 475-491 (2007).
20. Lockstone, H. E. et al. Gene expression profiling in the adult Down syndrome brain. Genomics 90, 647-660 (2007).
21. Vilardell, M. et al. Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 12, 229-2164-12-229 (2011).
22. Goodliffe, J. W., Olmos-Serrano, J. L., Aziz, N. M., Guedj, F., Bianchi, D. W. & Haydar, T. F. Absence of prenatal forebrain defects in the Dp(16)1Yey/+ mouse model of Down syndrome. J Neurosci 36, 2926-44 (2015).
23. Dauphinot, L. et al. The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum. Mol. Genet. 14, 373-384 (2005).
24. Ling, K. H. et al. Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks. BMC Genomics 15, 624-2164-15-624 (2014).
25. Saran, N. G., Pletcher, M. T., Natale, J. E., Cheng, Y. & Reeves, R. H. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum. Mol. Genet. 12, 2013-2019 (2003).
26. Duchon, A. et al. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm. Genome 22, 674-684 (2011).
27. Conti, A. et al. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics 8, 268 (2007).
28. Pereira, P. L. et al. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of Down syndrome. Hum. Mol. Genet. 18, 4756-4769 (2009).
29. Yu, T. et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res. 1366, 162-171 (2010).
30. Zhang, L. et al. Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndromerelated developmental cognitive deficits. Hum. Mol. Genet. 23, 578-589 (2014).
31. Block, A., Ahmed, M. M., Dhanasekaran, A. R., Tong, S. & Gardiner, K. J. Sex differences in protein expression in the mouse brain and their perturbations in a model of Down syndrome. Biol. Sex. Differ. 6, 24-015-0043-9. eCollection 2015 (2015).
32. Tsukahara, F. et al. Molecular characterization of the mouse mtprd gene, a homologue of human TPRD: unique gene expression suggesting its critical role in the pathophysiology of Down syndrome. J. Biochem. 123, 1055-1063 (1998).
33. Berto, G. E. et al. The DCR protein TTC3 affects differentiation and Golgi compactness in neurons through specific actin-regulating pathways. PLoS One 9, e93721 (2014).
34. Toker, A. TTC3 ubiquitination terminates Akt-ivation. Dev. Cell. 17, 752-754 (2009).
35. Zhang, Z., Yang, H. & Wang, H. The histone H2A deubiquitinase USP16 interacts with HERC2 and fine-tunes cellular response to DNA damage. J. Biol. Chem. 289, 32883-32894 (2014).
36. Zhuo, X. et al. Usp16 regulates kinetochore localization of Plk1 to promote proper chromosome alignment in mitosis. J. Cell Biol. 210, 727-735 (2015).
37. Joo, H. Y. et al. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 449, 1068-1072 (2007).
38. Adorno, M. et al. Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature 501, 380-384 (2013).
39. Xu, J. C., Dawson, V. L. & Dawson, T. M. Usp16: key controller of stem cells in Down syndrome. EMBO J. 32, 2788-2789 (2013).
40. Sheltzer, J. M., Torres, E. M., Dunham, M. J. & Amon, A. Transcriptional consequences of aneuploidy. Proc. Natl. Acad. Sci. USA 109, 12644-12649 (2012).
41. Hutaff-Lee, C., Cordeiro, L. & Tartaglia, N. Cognitive and medical features of chromosomal aneuploidy. Handb. Clin. Neurol. 111, 273-279 (2013).
42. Adams, D. J. & Clark, D. A. Common genetic and epigenetic syndromes. Pediatr. Clin. North Am. 62, 411-426 (2015).
43. Guihard-Costa, A. M., Khung, S., Delbecque, K., Menez, F. & Delezoide, A. L. Biometry of face and brain in fetuses with trisomy 21. Pediatr. Res. 59, 33-38 (2006).
44. Wisniewski, K. E., Laure-Kamionowska, M. & Wisniewski, H. M. Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down's syndrome. N. Engl. J. Med. 311, 1187-1188 (1984).
45. Tyler, W. A. & Haydar, T. F. Multiplex genetic fate mapping reveals a novel route of neocortical neurogenesis, which is altered in the Ts65Dn mouse model of Down syndrome. J. Neurosci. 33, 5106-5119 (2013).
46. Chakrabarti, L., Galdzicki, Z. & Haydar, T. F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 27, 11483-11495 (2007).
47. Necchi, D., Lomoio, S. & Scherini, E. Axonal abnormalities in cerebellar Purkinje cells of the Ts65Dn mouse. Brain Res. 1238, 181-188 (2008).
48. Ishihara, K. et al. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb. Cortex 20, 1131-1143 (2010).
49. Alves-Sampaio, A., Troca-Marin, J. A. & Montesinos, M. L. NMDA-mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome. J. Neurosci. 30, 13537-13548 (2010).
50. Jiang, J. et al. Translating dosage compensation to trisomy 21. Nature 500, 296-300 (2013).
51. Hibaoui, Y. et al. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. EMBO Mol. Med. 6, 259-277 (2014).
52. Biron-Shental, T., Liberman, M., Sharvit, M., Sukenik-Halevy, R. & Amiel, A. Amniocytes from aneuploidy embryos have enhanced random aneuploidy and signs of senescence-can these findings be related to medical problems? Gene 562, 232-235 (2015).
53. Sukenik-Halevy, R., Biron-Shental, T., Sharony, R., Fejgin, M. D. & Amiel, A. Telomeres in trisomy 21 amniocytes. Cytogenet. Genome Res. 135, 12-18 (2011).
54. Amiel, A. et al. Senescence in amniocytes and placentas from trisomy 21 pregnancies. J. Matern. Fetal. Neonatal Med. 26, 1086-1089 (2013).
55. Francis, Y. I. et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimers Dis. 18, 131-139 (2009).
56. Ellis, J. M. et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ 336, 594-597 (2008).
57. Blehaut, H. et al. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. PLoS One 5, e8394 (2010).
58. Heller, J. H. et al. Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up. J. Child Adolesc. Psychopharmacol. 20, 517-520 (2010).
59. Boada, R. et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl. Psychiatry. 2, e141 (2012).
60. Moran, T. H. et al. The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol. Behav. 77, 403-409 (2002).
61. Lobaugh, N. J. et al. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch. Pediatr. Adolesc. Med. 155, 442-448 (2001).
62. Black, S. L. Piracetam therapy for Down syndrome: a rush to judgment? Arch. Pediatr. Adolesc. Med. 155, 1176; author reply 1177-8 (2001).
63. Croom, J. Piracetam study: poorly designed and misinterpreted. Arch. Pediatr. Adolesc. Med. 155, 1176-1178 (2001).
64. Stagni, F. et al. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Neurobiol. Dis. 74, 204-218 (2015).
65. Guidi, S. et al. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Brain 137, 380-401 (2014).
66. Heinen, M. et al. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast. 2012, 467251 (2012).
67. Costa, A. C., Scott-McKean, J. J. & Stasko, M. R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33, 1624-1632 (2008).
68. Rueda, N. et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J. Alzheimers Dis. 21, 277-290 (2010).
69. Boada, R. et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl. Psychiatry. 2, e141 (2012).
70. Hanney, M. et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379, 528-536 (2012).